YARROW BIOSCIENCE, INC. Costs and Expenses
YARROW BIOSCIENCE, INC. (YARW) reported Costs and Expenses of $3.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-13
- YARROW BIOSCIENCE, INC. costs and expenses for the quarter ending 2026-06-30 was $3.20M, a 57.97% decline year-over-year.
- YARROW BIOSCIENCE, INC. costs and expenses for the quarter ending 2026-03-31 was $3.90M, a 58.48% decline year-over-year.
- YARROW BIOSCIENCE, INC. costs and expenses for the quarter ending 2025-06-30 was $7.61M, a 28.16% decline year-over-year.
- YARROW BIOSCIENCE, INC. costs and expenses for the quarter ending 2025-03-31 was $9.40M, a 25.69% increase year-over-year.
- YARROW BIOSCIENCE, INC. costs and expenses for fiscal 2023 was $29.68M, a 14.64% decline from fiscal 2022.
- YARROW BIOSCIENCE, INC. costs and expenses for fiscal 2022 was $34.77M, a 12.73% decline from fiscal 2021.
- YARROW BIOSCIENCE, INC. costs and expenses for fiscal 2021 was $39.84M, a 85.36% decline from fiscal 2020.
- YARROW BIOSCIENCE, INC. costs and expenses for fiscal 2020 was $272.15M, a 182.56% increase from fiscal 2019.
| Period end | Costs and Expenses 3 month | Costs and Expenses 3 month as first filed | Costs and Expenses 6 month | Costs and Expenses 6 month as first filed | Costs and Expenses 9 month | Costs and Expenses 9 month as first filed | Costs and Expenses 12 month | Costs and Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.20M 10-Q · filed 2026-08-13 | $7.10M 10-Q · filed 2026-08-13 | ||||||
| 2026-03-31 | $3.90M S-4/A · filed 2026-06-03 | |||||||
| 2025-12-31 | $30.32M S-4/A · filed 2026-06-03 | |||||||
| 2025-06-30 | $7.61M 10-Q · filed 2026-08-13 | $17.01M 10-Q · filed 2026-08-13 | $29.86M derived: sum of 3 quarters · filed 2026-08-13 | $43.08M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $9.40M S-4/A · filed 2026-06-03 | $22.25M derived: sum of 2 quarters · filed 2026-06-03 | $35.47M derived: sum of 3 quarters · filed 2026-06-03 | $46.06M derived: sum of 4 quarters · filed 2026-06-03 | ||||
| 2024-12-31 | $12.85M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-06-03 | $26.07M derived: sum of 2 quarters · filed 2026-06-03 | $36.66M derived: sum of 3 quarters · filed 2026-06-03 | $44.14M S-4/A · filed 2026-06-03 | ||||
| 2024-09-30 | $13.21M 10-Q · filed 2024-11-07 | $23.81M derived: sum of 2 quarters · filed 2025-08-14 | $31.28M 10-Q · filed 2024-11-07 | $38.19M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-06-30 | $10.59M 10-Q · filed 2025-08-14 | $18.07M 10-Q · filed 2025-08-14 | $24.98M derived: sum of 3 quarters · filed 2025-08-14 | $31.33M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $7.48M 10-Q · filed 2025-05-08 | $14.39M derived: sum of 2 quarters · filed 2025-05-08 | $20.73M derived: sum of 3 quarters · filed 2025-05-08 | $31.19M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $6.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $13.26M derived: sum of 2 quarters · filed 2025-03-06 | $23.71M derived: sum of 3 quarters · filed 2025-03-06 | $29.68M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | $6.35M 10-Q · filed 2024-11-07 | $16.80M derived: sum of 2 quarters · filed 2024-11-07 | $22.77M 10-Q · filed 2024-11-07 | $30.77M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $10.45M 10-Q · filed 2024-08-14 | $16.43M 10-Q · filed 2024-08-14 | $24.42M derived: sum of 3 quarters · filed 2024-08-14 | $33.92M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $5.97M 10-Q · filed 2024-05-09 | $13.96M derived: sum of 2 quarters · filed 2024-05-09 | $23.46M derived: sum of 3 quarters · filed 2024-05-09 | $31.88M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $7.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $17.49M derived: sum of 2 quarters · filed 2024-03-01 | $25.90M derived: sum of 3 quarters · filed 2024-03-01 | $34.77M 10-K · filed 2024-03-01 | ||||
| 2022-09-30 | $9.50M 10-Q · filed 2023-11-13 | $17.91M derived: sum of 2 quarters · filed 2023-11-13 | $26.78M 10-Q · filed 2023-11-13 | $35.90M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $8.41M 10-Q · filed 2023-08-14 | $17.28M 10-Q · filed 2023-08-14 | $26.40M derived: sum of 3 quarters · filed 2023-08-14 | $37.30M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $8.87M 10-Q · filed 2023-05-11 | $17.99M derived: sum of 2 quarters · filed 2023-05-11 | $28.89M derived: sum of 3 quarters · filed 2023-05-11 | $38.73M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $9.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $20.02M derived: sum of 2 quarters · filed 2023-03-14 | $29.86M derived: sum of 3 quarters · filed 2023-03-14 | $39.84M 10-K · filed 2023-03-14 | $79.44M 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $10.90M 10-Q · filed 2022-11-14 | $20.81M 10-Q · filed 2021-11-10 | $20.74M derived: sum of 2 quarters · filed 2022-11-14 | $30.72M 10-Q · filed 2022-11-14 | $66.01M 10-Q · filed 2021-11-10 | $56.47M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $9.84M 10-Q · filed 2022-08-12 | $22.24M 10-Q · filed 2021-08-12 | $19.82M 10-Q · filed 2022-08-12 | $45.19M 10-Q · filed 2021-08-12 | $45.56M derived: sum of 3 quarters · filed 2022-08-12 | $71.95M derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2021-03-31 | $9.99M 10-Q · filed 2022-05-12 | $22.95M 10-Q · filed 2021-05-06 | $35.73M derived: sum of 2 quarters · filed 2022-05-12 | $62.12M derived: sum of 3 quarters · filed 2022-05-12 | $240.77M derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $25.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $52.13M derived: sum of 2 quarters · filed 2022-03-17 | $230.78M derived: sum of 3 quarters · filed 2022-03-17 | $272.15M 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $26.39M 10-Q · filed 2021-11-10 | $26.76M 10-Q · filed 2020-11-05 | $205.04M derived: sum of 2 quarters · filed 2021-11-10 | $246.41M 10-Q · filed 2021-11-10 | $247.26M 10-Q · filed 2020-11-05 | $283.97M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $178.65M 10-Q · filed 2021-08-12 | $178.87M 10-Q · filed 2020-08-06 | $220.02M 10-Q · filed 2021-08-12 | $220.50M 10-Q · filed 2020-08-06 | $257.58M derived: sum of 3 quarters · filed 2021-08-12 | $280.78M derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $41.37M 10-Q · filed 2021-05-06 | $41.64M 10-Q · filed 2020-05-11 | $78.93M derived: sum of 2 quarters · filed 2021-05-06 | $102.13M derived: sum of 3 quarters · filed 2021-05-06 | $121.49M derived: sum of 4 quarters · filed 2021-05-06 | |||
| 2019-12-31 | $37.57M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $60.77M derived: sum of 2 quarters · filed 2021-03-04 | $80.12M derived: sum of 3 quarters · filed 2021-03-04 | $96.32M 10-K · filed 2021-03-04 | ||||
| 2019-09-30 | $23.20M 10-Q · filed 2020-11-05 | $42.56M derived: sum of 2 quarters · filed 2020-11-05 | $58.75M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $19.36M 10-Q · filed 2020-08-06 | $35.55M 10-Q · filed 2020-08-06 | ||||||
| 2019-03-31 | $16.19M 10-Q · filed 2020-05-11 | |||||||
| 2018-12-31 | $78.49M 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |